MannKind (NASDAQ:MNKD) Stock Gets Price Target Reduction from Truist Financial

Posted by George Bondi on Oct 10th, 2026

MannKind (NASDAQ:MNKD – Free Report) had its price objective trimmed by Truist Financial from $6.00 to $5.00 in a research note issued to investors on Wednesday morning,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other equities research analysts have also issued reports on MNKD. Zacks Research raised MannKind from a “strong sell” rating to a “hold” rating in a research report on Monday, October 5th. Wall Street Zen downgraded shares of MannKind from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d)” rating on shares of MannKind in a research note on Friday, October 2nd. HC Wainwright reissued a “buy” rating on shares of MannKind in a report on Thursday, July 23rd. Finally, Wells Fargo & Company reduced their price target on shares of MannKind from $14.00 to $13.00 and set an “overweight” rating on the stock in a research report on Thursday, August 6th. Seven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.84.

Read Our Latest Report on MNKD

MannKind Stock Down 3.8%

Shares of MannKind stock opened at $3.29 on Wednesday. The firm has a market cap of $1.06 billion, a P/E ratio of -25.31 and a beta of 1.09. MannKind has a fifty-two week low of $2.23 and a fifty-two week high of $6.51. The business has a 50-day moving average price of $3.82 and a 200 day moving average price of $3.54.

MannKind (NASDAQ:MNKD – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.01). The firm had revenue of $109.37 million for the quarter, compared to analyst estimates of $108.08 million. The company’s quarterly revenue was up 43.0% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.05 EPS. As a group, equities research analysts anticipate that MannKind will post -0.20 earnings per share for the current year.

Insider Activity

In related news, Director Steven Binder sold 39,051 shares of the business’s stock in a transaction that occurred on Friday, September 25th. The stock was sold at an average price of $3.29, for a total transaction of $128,477.79. Following the completion of the transaction, the director owned 713,258 shares in the company, valued at $2,346,618.82. The trade was a 5.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders sold 111,660 shares of company stock valued at $414,881. Company insiders own 2.60% of the company’s stock.

Institutional Investors Weigh In On MannKind

Several large investors have recently added to or reduced their stakes in MNKD. Wellington Management Group LLP grew its position in MannKind by 138.9% in the 2nd quarter. Wellington Management Group LLP now owns 7,844,807 shares of the biopharmaceutical company’s stock worth $33,419,000 after purchasing an additional 4,561,628 shares during the last quarter. Frazier Life Sciences Management L.P. raised its holdings in shares of MannKind by 11.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 6,600,000 shares of the biopharmaceutical company’s stock valued at $28,116,000 after buying an additional 700,000 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in shares of MannKind by 11.5% during the first quarter. Dimensional Fund Advisors LP now owns 4,953,295 shares of the biopharmaceutical company’s stock worth $12,134,000 after buying an additional 509,692 shares during the period. 180 Wealth Advisors LLC boosted its position in shares of MannKind by 45.0% during the first quarter. 180 Wealth Advisors LLC now owns 4,291,703 shares of the biopharmaceutical company’s stock worth $10,515,000 after buying an additional 1,332,759 shares during the period. Finally, Braidwell LP bought a new position in MannKind in the 2nd quarter worth approximately $14,733,000. 49.55% of the stock is owned by institutional investors and hedge funds.

About MannKind

(Get Free Report)

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF).